// App-Quantinova.ai

: When are atrial fibrillation patients at risk to discontinue anticoagulation treatment? Results from the GLORIA-AF Registry

Researchers

Presenter

  • M Paquette

Principal Investigators

  • M V Huisman

  • G Y H Lip

  • H.-C Diener

  • S J Dubner

  • J L Halperin

  • K J Rothman

  • C S Ma

  • L Riou Franca

Medical Centers

  • Boehringer Ingelheim Corporation, Burlington, Canada

  • Leiden University Medical Centre, Leiden, Netherlands

  • University of Birmingham, Birmingham, United Kingdom

  • University Hospital of Essen, Essen, Germany

  • Clinica y Maternidad Suizo Argentina, Buenso Aires, Argentina

  • The Mount Sinai School of Medicine, New York, United States

  • RTI Health Solutions, Durham, NC, United States

  • Beijing Children's Hospital, Beijing, China (People's Republic)

  • Boehringer Ingelheim Corporation, Ridgefield, CT, United States of America

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

Locations

  • Canada

  • Netherlands

  • United Kingdom

  • Germany

  • Argentina

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved